Cargando…

Clinical efficacy and safety of afatinib in the treatment of non-small-cell lung cancer in Chinese patients

Compared with various malignant tumors, lung cancer has high incidence and the highest mortality worldwide. Non-small-cell lung cancer (NSCLC), the most common kind of lung cancer, is still a great threat to the world, including China. Surgery, platinum-based chemotherapy, and radiotherapy are still...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Lei-Yun, Cui, Jia-Jia, Guo, Ao-Xiang, Yin, Ji-Ye
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5790073/ https://www.ncbi.nlm.nih.gov/pubmed/29416353 http://dx.doi.org/10.2147/OTT.S136579

Ejemplares similares

Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
por: Kim, Youjin, et al.
Publicado: (2019)

Afatinib in Non–Small Cell Lung Cancer
por: Wirth, Scott M.
Publicado: (2015)

The Efficacy and Safety of Afatinib in Non-Small Cell Lung Cancer Patients with Brain Metastasis: A Meta-Analysis
por: Jin, Hui, et al.
Publicado: (2023)

Efficacy and safety of afatinib in a Chinese population with advanced lung adenocarcinoma with sensitive EGFR mutations
por: Wang, Shouzheng, et al.
Publicado: (2019)

Effect of Dose Adjustments on the Safety and Efficacy of Afatinib in Chinese Patients with EGFR-Mutated Non-Small Cell Lung Cancer Who Participated in the LUX-Lung Clinical Trial Program
por: Tu, Hai-Yan, et al.
Publicado: (2020)

Clinical and comparative utility of afatinib in non-small cell lung cancer
por: D’Arcangelo, Manolo, et al.
Publicado: (2014)

Afatinib for the treatment of metastatic non-small cell lung cancer
por: Joshi, Monika, et al.
Publicado: (2015)

Sarcopenia as a predictor of initial administration dose of afatinib in patients with advanced non‐small cell lung cancer
por: Nie, Xin, et al.
Publicado: (2021)

Efficacy and Resistance of Afatinib in Chinese Non-Small Cell Lung Cancer Patients With HER2 Alterations: A Multicenter Retrospective Study
por: Song, Zhengbo, et al.
Publicado: (2021)

Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer
por: Lee, Youngjoo, et al.
Publicado: (2017)

Efficacy and Safety Results of the Afatinib Expanded Access Program
por: Kim, Edward S., et al.
Publicado: (2017)

Efficacy and Safety of Afatinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with EGFR Mutations: A Meta-Analysis of Real-World Evidence
por: Zhang, Lemeng, et al.
Publicado: (2021)

A Retrospective Comparison of the Clinical Efficacy of Gefitinib, Erlotinib, and Afatinib in Japanese Patients With Non-Small Cell Lung Cancer
por: Fujiwara, Atsushi, et al.
Publicado: (2018)

The efficacy of afatinib in patients with HER2 mutant non-small cell lung cancer: a meta-analysis
por: Zhou, Niya, et al.
Publicado: (2020)

Effects of Afatinib on Development of Non-Small-Cell Lung Cancer by Regulating Activity of Wnt/β-Catenin Signaling Pathway
por: Wu, Yue, et al.
Publicado: (2022)

Efficacy and dose of afatinib in patients with non‐small cell lung cancer after failure of prior gefitinib or erlotinib treatment
por: Choi, Hayoung, et al.
Publicado: (2021)

CNS efficacy of afatinib as first-line treatment in advanced non-small cell lung cancer patients with EGFR mutations
por: Kang, Liping, et al.
Publicado: (2023)

Gene-gene and gene-environment interaction data for platinum-based chemotherapy in non-small cell lung cancer
por: Wang, Lei-Yun, et al.
Publicado: (2018)

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
por: Schuler, M., et al.
Publicado: (2016)

Population pharmacokinetics of afatinib and exposure-safety relationships in Japanese patients with EGFR mutation-positive non-small cell lung cancer
por: Nakao, Keiko, et al.
Publicado: (2019)

Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience
por: Ricciuti, Biagio, et al.
Publicado: (2018)

Identification and Validation of Afatinib Potential Drug Resistance Gene BIRC5 in Non-Small Cell Lung Cancer
por: Zhu, Xiaoxi, et al.
Publicado: (2021)

Synergistic Effect of HAD-B1 and Afatinib Against Gefitinib Resistance of Non-Small Cell Lung Cancer
por: Song, Si Yeon, et al.
Publicado: (2022)

Afatinib Overcomes Pemetrexed-Acquired Resistance in Non-Small Cell Lung Cancer Cells Harboring an EML4-ALK Rearrangement
por: Kwon, Ji-Hyun, et al.
Publicado: (2019)

Non-small-cell lung cancer with epidermal growth factor receptor L861Q-L833F compound mutation benefits from both afatinib and osimertinib: A case report
por: Zhang, Yao, et al.
Publicado: (2021)

Afatinib and Dacomitinib Efficacy, Safety, Progression Patterns, and Resistance Mechanisms in Patients with Non-Small Cell Lung Cancer Carrying Uncommon EGFR Mutations: A Comparative Cohort Study in China (AFANDA Study)
por: Li, Hong-Shuai, et al.
Publicado: (2022)

The role of CSDE1 in translational reprogramming and human diseases
por: Guo, Ao-Xiang, et al.
Publicado: (2020)

Efficacy of Afatinib in a Previously-Treated Patient with Non-Small Cell Lung Cancer Harboring HER2 Mutation: Case Report
por: Park, Cheol Kyu, et al.
Publicado: (2017)

The Impact of Afatinib on Survival in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials
por: Wang, Chi, et al.
Publicado: (2019)

Chinese Medicine Treatment for Afatinib-Induced Paronychia
por: Yang, Pei-Yuu, et al.
Publicado: (2017)

Response of Leptomeningeal Metastases in EGFR-Mutated Non-Small-Cell Lung Cancer to Afatinib in the Absence of Radiotherapy
por: Llinás-Quintero, Néstor, et al.
Publicado: (2019)

Relationship between Plasma Concentrations of Afatinib and the Onset of Diarrhea in Patients with Non-Small Cell Lung Cancer
por: Yokota, Hayato, et al.
Publicado: (2021)

Inhibition of osteopontin overcomes acquired resistance to afatinib in EGFR-mutant non-small-cell lung cancer
por: Zhang, Hongye, et al.
Publicado: (2020)

Takotsubo cardiomyopathy Afatinib-related in a non-small cell lung cancer patient: Case report
por: Ramos, German E., et al.
Publicado: (2022)

Long-term efficacy of afatinib in a patient with squamous cell carcinoma of the lung and multiple ERBB family aberrations: afatinib in ERBB+ lung squamous cell carcinoma
por: Jian, Hong, et al.
Publicado: (2019)

Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib
por: Lee, Victor H. F., et al.
Publicado: (2016)

Transformation to small cell lung cancer after first-line afatinib treatment
por: Shiroyama, Takayuki, et al.
Publicado: (2018)

Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice
por: Brückl, Wolfgang M., et al.
Publicado: (2021)

Change from lung adenocarcinoma to small cell lung cancer as a mechanism of resistance to afatinib
por: Manca, Paolo, et al.
Publicado: (2017)

Combination of afatinib with cetuximab in patients with EGFR-mutant non-small-cell lung cancer resistant to EGFR inhibitors
por: Ribeiro Gomes, Jéssica, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_t3ivhk8tlk5u8ae4v97tdvdbme